{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T14:44:19Z","timestamp":1791902659380,"version":"4.3.4"},"reference-count":32,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T00:00:00Z","timestamp":1770336000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T00:00:00Z","timestamp":1770336000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Dermatology"],"published-print":{"date-parts":[[2026,4]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>\n                    Ritlecitinib is an oral JAK3\/TEC family kinase inhibitor approved for individuals aged\u2009\u2265\u200912\u2009years with severe alopecia areata. Here we report interim efficacy and safety results with ritlecitinib up to Month 24 in the Asian subpopulation from the ALLEGRO phase 2b\/3 and ALLEGRO\u2010LT studies. Data are reported for participants with Severity of Alopecia Tool score\u2009\u2265\u200950 who received ritlecitinib 50\u2009mg with (200\/50\u2010mg group) or without (50\u2010mg group) an initial 4\u2010week 200\u2010mg daily loading dose in ALLEGRO\u20102b\/3, and continued ritlecitinib 50 mg in ALLEGRO\u2010LT. In long\u2010term studies, it is common for summaries at later time points to reflect participants who remained in the study, tolerated the drug, and had a positive treatment response. To account for this, efficacy summaries were presented both as observed and by using the last observation carried forward method. At Month 12, 51.7% and 44.7% (last observation carried forward) of Asian participants in the 50\u2010mg (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200958) and 200\/50\u2010mg groups (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200947), respectively, achieved Severity of Alopecia Tool score\u2009\u2264\u200920 (\u2264\u200920% scalp hair loss); the respective proportions were 50.0% and 47.8% at Month 24. Of participants who achieved Severity of Alopecia Tool score\u2009\u2264\u200920 at Month 12 in the 50\u2010mg and 200\/50\u2010mg groups, 68.2% and 86.7% sustained this response through Month 24, respectively. At Month 12, 74.0% and 57.9% of participants in the 50\u2010mg and 200\/50\u2010mg groups, respectively, had an eyebrow hair regrowth response; at Month 24, the proportions were 72.0% and 48.7%. At Month 12, 65.1% and 54.1% of participants in the 50\u2010mg and 200\/50\u2010mg groups, respectively, had an eyelash hair regrowth response; the proportions were 65.1% and 52.8% at Month 24. The proportion of participants with a Patients' Global Impression of Change response of \u201cmoderately\u201d or \u201cgreatly\u201d improved since baseline increased through Month 24 in both groups. Ritlecitinib had an acceptable safety profile, consistent with that in the overall population. Overall, ritlecitinib 50\u2009mg (\u00b1200\u2010mg loading dose) demonstrated clinically meaningful and sustained efficacy through Month 24 in the Asian subpopulation, consistent with results in the overall population.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Trial Registration:<\/jats:bold>\n                    <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"http:\/\/clinicaltrials.gov\">ClinicalTrials.gov<\/jats:ext-link>\n                    : NCT04006457.\n                  <\/jats:p>","DOI":"10.1111\/1346-8138.70154","type":"journal-article","created":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T09:36:12Z","timestamp":1770370572000},"page":"578-586","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Efficacy and Safety of Ritlecitinib in the Asian Subpopulation of the\n                    <scp>ALLEGRO<\/scp>\n                    \u20102b\/3 and\n                    <scp>ALLEGRO<\/scp>\n                    \u2010\n                    <scp>LT<\/scp>\n                    Clinical Studies for Alopecia Areata"],"prefix":"10.1111","volume":"53","author":[{"given":"Rie","family":"Ueki","sequence":"first","affiliation":[{"name":"Juntendo University  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0977-4443","authenticated-orcid":false,"given":"Masato","family":"Mizuashi","sequence":"additional","affiliation":[{"name":"Tohoku University Graduate School of Medicine  Sendai Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9059-4097","authenticated-orcid":false,"given":"Kazutoshi","family":"Harada","sequence":"additional","affiliation":[{"name":"Department of Dermatology Tokyo Medical University  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingqi","family":"Zhang","sequence":"additional","affiliation":[{"name":"The First Affiliated Hospital, Sun Yat\u2010Sen University  Guangzhou China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenyu","family":"Wu","sequence":"additional","affiliation":[{"name":"Huashan Hospital Affiliated to Fudan University  Shanghai China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen\u2010Hung","family":"Chung","sequence":"additional","affiliation":[{"name":"Department of Dermatology Chang Gung Memorial Hospital  Taipei Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ohsang","family":"Kwon","sequence":"additional","affiliation":[{"name":"Department of Dermatology Seoul National University College of Medicine  Seoul South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Luo","sequence":"additional","affiliation":[{"name":"Pfizer R&amp;D China  Shanghai China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-3621-7446","authenticated-orcid":false,"given":"Victoria","family":"Basey","sequence":"additional","affiliation":[{"name":"Pfizer Inc  Tadworth UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8581-6647","authenticated-orcid":false,"given":"Robert","family":"Wolk","sequence":"additional","affiliation":[{"name":"Pfizer Inc  Groton Connecticut USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nanzhi","family":"Shi","sequence":"additional","affiliation":[{"name":"Pfizer R&amp;D Japan G.K.  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1539-3129","authenticated-orcid":false,"given":"Kayo","family":"Fujita","sequence":"additional","affiliation":[{"name":"Pfizer R&amp;D Japan G.K.  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yimeng","family":"Shen","sequence":"additional","affiliation":[{"name":"Pfizer China PBG  Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomohiro","family":"Hirose","sequence":"additional","affiliation":[{"name":"Pfizer Japan Inc  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,2,6]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2014.10.014"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2019.08.032"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.2147\/CCID.S245649"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.14959"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.20628"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1346-8138.2011.01209.x"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.16615"},{"key":"e_1_2_10_9_1","first-page":"668","article-title":"Alopecia Areata in China: A Survey on Prevalence in 6 Cities","volume":"42","author":"TingLin W.","year":"2009","journal-title":"Chinese Journal of Dermatology"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2017.11"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2019.06.1300"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/ajd.12941"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jisp.2017.10.007"},{"key":"e_1_2_10_14_1","first-page":"397","article-title":"Epidemiology and Burden of Alopecia Areata: A Systematic Review","volume":"8","author":"Villasante Fricke A. C.","year":"2015","journal-title":"Clinical, Cosmetic and Investigational Dermatology"},{"key":"e_1_2_10_15_1","unstructured":"Olumiant (baricitinib). Prescribing Information. Lilly USA; 2022 https:\/\/pi.lilly.com\/us\/olumiant\u2010uspi.pdf."},{"key":"e_1_2_10_16_1","unstructured":"\u201cU.S. FDA Approves LEQSELVI (deuruxolitinib) an Oral JAK Inhibitor for the Treatment of Severe Alopecia Areata 2024\u201d https:\/\/sunpharma.com\/wp\u2010content\/uploads\/2024\/07\/Sunpharma\u2010LEQSELVI\u2010Approval\u2010Scenario\u2010Press\u2010Release.pdf."},{"key":"e_1_2_10_17_1","unstructured":"Litfulo (ritlecitinib). Prescribing Information. Pfizer; 2023 https:\/\/labeling.pfizer.com\/ShowLabeling.aspx?id=19638."},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)00222-2"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.17539"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1093\/bjd\/ljae365"},{"key":"e_1_2_10_21_1","article-title":"Integrated Safety Analysis of Ritlecitinib, an Oral JAK3\/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata From the ALLEGRO Clinical Trial Program","author":"King B.","year":"2024","journal-title":"American Journal of Clinical Dermatology"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.20526"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.25251\/skin.8.supp.394"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2019.05.086"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.16360"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2013.3049"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.16364"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/8879343"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jisp.2020.05.007"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.4103\/0974-7753.189005"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.4103\/ijt.ijt_99_20"},{"key":"e_1_2_10_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jisp.2020.04.006"},{"key":"e_1_2_10_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2022.02.019"}],"container-title":["The Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1346-8138.70154","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/1346-8138.70154","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1346-8138.70154","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T16:09:35Z","timestamp":1776096575000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/1346-8138.70154"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,6]]},"references-count":32,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["10.1111\/1346-8138.70154"],"URL":"https:\/\/doi.org\/10.1111\/1346-8138.70154","archive":["Portico"],"relation":{},"ISSN":["0385-2407","1346-8138"],"issn-type":[{"value":"0385-2407","type":"print"},{"value":"1346-8138","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,6]]},"assertion":[{"value":"2025-09-17","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-12-27","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-06","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}